Cytodyn Inc (CYDY)

[JPG77]

Glaxo’s New Focus After Haleon Spinoff Shines a Light on CytoDyn as a Takeover Target

"When the clinical hold is lifted, the written-off indications the drug is being developed for (HIV, mTNBC and other cancers, COVID, MS, and NASH) will come back into play and investors will remember why, just a short time ago, investors were willing to pay up to $5-10 for this platform technology before cancer or NASH results were known. This could be an enormous value infection point, but in the meantime, the breadcrumbs show how perfect leronlimab and the corprate culture fit are for GSK. The deal makes too much sense—the fit is so ideal it cannot be ignored. This is what is capturing investors’ minds as they see the breadcrumbs. If GSK shows any interest at all it could be soon and investors are going to want to be fully loaded for this kind of surprise event."

https://insiderfinancial.com/glaxos-new-focus-after-haleon-spinoff-shines-a-light-on-cytodyn-otcmkts-cydy-as-a-takeover-target/183360/